Cargando…
Stem cell translational medicine: The Tianjin model revisited
Stem cells hold great promise for cell therapy to treat a wide spectrum of intractable diseases. Despite enthusiasm for stem cell therapy, the clinical and translational research of stem cells overall has been a slow and cumbersome process. This article uses the “technological system” as a framework...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560194/ https://www.ncbi.nlm.nih.gov/pubmed/34724723 http://dx.doi.org/10.1002/sctm.20-0494 |
_version_ | 1784592892178726912 |
---|---|
author | Chen, Haidan |
author_facet | Chen, Haidan |
author_sort | Chen, Haidan |
collection | PubMed |
description | Stem cells hold great promise for cell therapy to treat a wide spectrum of intractable diseases. Despite enthusiasm for stem cell therapy, the clinical and translational research of stem cells overall has been a slow and cumbersome process. This article uses the “technological system” as a framework to analyze the Tianjin model of stem cell translational medicine. It shows how heterogeneous elements interact with one another and relate to scientific, technological, social, economic, and political variables in order to fulfill the system goal of producing cell therapy in China. Then the strengths and weaknesses of the Tianjin model are compared with translational programs in other countries and the implications for the cell therapy industry are discussed. |
format | Online Article Text |
id | pubmed-8560194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85601942021-11-08 Stem cell translational medicine: The Tianjin model revisited Chen, Haidan Stem Cells Transl Med Perspectives Stem cells hold great promise for cell therapy to treat a wide spectrum of intractable diseases. Despite enthusiasm for stem cell therapy, the clinical and translational research of stem cells overall has been a slow and cumbersome process. This article uses the “technological system” as a framework to analyze the Tianjin model of stem cell translational medicine. It shows how heterogeneous elements interact with one another and relate to scientific, technological, social, economic, and political variables in order to fulfill the system goal of producing cell therapy in China. Then the strengths and weaknesses of the Tianjin model are compared with translational programs in other countries and the implications for the cell therapy industry are discussed. John Wiley & Sons, Inc. 2021-11-01 /pmc/articles/PMC8560194/ /pubmed/34724723 http://dx.doi.org/10.1002/sctm.20-0494 Text en © 2021 The Author. stem cells translational medicine published by Wiley Periodicals LLC on behalf of AlphaMed Press. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Perspectives Chen, Haidan Stem cell translational medicine: The Tianjin model revisited |
title | Stem cell translational medicine: The Tianjin model revisited |
title_full | Stem cell translational medicine: The Tianjin model revisited |
title_fullStr | Stem cell translational medicine: The Tianjin model revisited |
title_full_unstemmed | Stem cell translational medicine: The Tianjin model revisited |
title_short | Stem cell translational medicine: The Tianjin model revisited |
title_sort | stem cell translational medicine: the tianjin model revisited |
topic | Perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560194/ https://www.ncbi.nlm.nih.gov/pubmed/34724723 http://dx.doi.org/10.1002/sctm.20-0494 |
work_keys_str_mv | AT chenhaidan stemcelltranslationalmedicinethetianjinmodelrevisited |